Lincoln Financial Group Life Insurance Fit Review for Kidney Disease

Research Snapshot

Why Lincoln Financial Group Qualified for This Study

Questions This Section Answers

• Is Lincoln Financial Group a good choice for life insurance for kidney disease?
• Why did only two of seven AI platforms name Lincoln Financial Group for kidney disease applicants?

Lincoln Financial Group qualified because it is a large national carrier that sells fully underwritten term and permanent life products a kidney-disease buyer could apply for, and because two platforms named it during ranking discovery (google, perplexity). It did not qualify on kidney-specific underwriting evidence, because none was found.

The ranking-stage result was thin. Lincoln appeared on 2 of 7 platform responses, a 28.6% share, with an average listed rank of 3.0 and a best rank of 3. It finished seventh in the final ordering. Five platforms evaluated Lincoln's fit for this use case without naming it during ranking discovery, which is why the mention count is low relative to the seven fit evaluations.

The company's public individual life pages market term life and variable universal life insurance to individual buyers, providing fully underwritten products a kidney-disease applicant could apply for subject to underwriting ^[1]. Lincoln's principal life subsidiary appears in state insurance department records, supporting that it is an authorized carrier in at least some states ^[2].

What Lincoln did not supply is equally important. Its public individual life pages do not publish kidney-disease-specific underwriting guidelines, stage-based acceptability criteria, or a kidney impairment rating table ^[1]. That gap is the central reason this review lands on a mixed fit rather than a clear recommendation.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Kidney Disease

Questions This Section Answers

• Which Lincoln Financial Group product should a buyer with kidney disease choose: TermAccel, LifeElements, or a universal life policy?
• Does Lincoln TermAccel accept applicants with chronic kidney disease or dialysis?

The most relevant Lincoln products for this use case are fully underwritten term and permanent life insurance, particularly Lincoln TermAccel Level Term and Lincoln AssetEdge VUL. TermAccel is the product most often named, but it is also the product most clearly restricted for kidney disease.

TermAccel offers 10-, 15-, 20-, and 30-year level-premium periods, a $100,000 minimum face amount, and a $2.5 million maximum face amount, with issue-age limits varying by term and tobacco status ^[3]. Lincoln states TermAccel can be converted to qualifying Lincoln permanent life insurance before the end of the level-premium period or before attained age 70, whichever comes first ^[3]. Lincoln describes TermAccel as intended for people in good health, with a fully electronic application, automated processing, and possible lab waivers for qualifying applicants ^[4].

That positioning collides with Lincoln's own underwriting documents. Lincoln's TermAccel underwriting guide lists chronic kidney failure as a disqualifying condition ^[5]. An independent copy of the same guide reaches the same conclusion ^[7]. Lincoln's TermAccel prequalification checklist shows chronic kidney failure among conditions to screen for and notes labs or vitals if required ^[9]. Lincoln's TermAccel brochure likewise lists chronic kidney failure as disqualifying ^[10].

For permanent coverage, Lincoln's current public VUL page lists Lincoln AssetEdge VUL and Lincoln AssetEdge SVUL as current single-life and survivorship products ^[11]. The AssetEdge VUL fact sheet describes investment options, issue amounts, death-benefit options, and product features ^[12]. Lincoln's prospectus listing shows multiple VUL contract names and explains that products and features are state-specific ^[13]. The generic ranking-stage label "Lincoln VUL" does not identify one current contract, so the exact contract must be confirmed before purchase ^[11].

One platform identified a different pathway. Lincoln LifeElements Level Term is described in independent review material as designed for high-risk applicants with complex medical histories, with more flexible underwriting than TermAccel ^[14]. LifeElements is described as accommodating higher face amounts starting at $2.5 million ^[16]. Lincoln's LifeElements and universal life underwriting guidelines are restricted to financial professionals and not publicly accessible, so those claims cannot be verified from public documents ^[17].

Lincoln's hybrid product is a clearer exclusion. Lincoln MoneyGuard lists dialysis or kidney failure as an uninsurable condition on its Evidence of Insurability form ^[18]. Lincoln's MoneyGuard underwriting-at-a-glance lists dialysis or kidney failure as an underwriting concern ^[19], and the MoneyGuard presubmission tool lists dialysis treatment or chronic kidney disease among conditions to flag before submission ^[20]. Lincoln's WealthAccelerate IUL underwriting guidelines list kidney disease as an ineligible condition for accelerated underwriting ^[21], and WealthAccelerate prequalification materials list kidney disease, hypertension, and adverse MIB or prescription history as relevant underwriting concerns ^[23].

What the AI Platforms Agreed About

Questions This Section Answers

• Do all AI platforms agree that Lincoln Financial Group is a mixed fit for kidney disease life insurance?
• What do the platforms agree Lincoln Financial Group will not cover for a kidney disease applicant?

The platforms agreed on the core limitation: Lincoln's accelerated, simplified, and hybrid products are not available to applicants with chronic kidney failure or dialysis, and Lincoln does not publish kidney-specific underwriting rules for its fully underwritten products.

Five of seven platforms rated Lincoln a mixed fit (anthropic, google, grok, openai, perplexity), and two rated it uncertain (deepseek, kimi). No platform rated it a strong or clear fit. That distribution is the clearest consensus signal in the study.

The specific agreements:

• Lincoln's TermAccel underwriting guide lists chronic kidney failure as disqualifying ^[25].
• Lincoln's MoneyGuard materials list dialysis or kidney failure as uninsurable or as a flagged condition ^[28].
• Kidney disease triggers full underwriting requirements, including labs and vitals, rather than accelerated processing ^[32].
• Lincoln does not publish kidney-disease-specific premiums, rate tables, or class breaks ^[35].
• Independent kidney-underwriting sources describe general market tendencies, not Lincoln-specific decisions ^[38].

The platforms also agreed on the general underwriting factors that matter. An independent underwriting guide identifies renal disease risk factors including eGFR, proteinuria or albuminuria, progression, dialysis, transplant history, and comorbidities such as hypertension, diabetes, coronary disease, and peripheral vascular disease ^[38]. Independent consumer guidance describes life insurance options for people with kidney disease but does not verify or endorse Lincoln's underwriting approach ^[40].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Is Lincoln LifeElements a viable kidney disease pathway, or is that claim unverified?
• What is Lincoln Financial Group's actual eGFR cutoff for a standard versus table-rated offer?

The platforms disagreed on whether Lincoln has a viable pathway for kidney-disease applicants beyond TermAccel, and they were uniformly uncertain about Lincoln's actual approval thresholds.

The sharpest disagreement concerns LifeElements. One platform described Lincoln LifeElements Level Term as designed for high-risk applicants with complex medical histories and more flexible underwriting than TermAccel ^[41]. Another platform concluded that Lincoln is not mentioned in any CKD-specific carrier recommendations across reviewed sources and that Lincoln lacks guaranteed-issue or graded-benefit products entirely ^[43]. Both positions can be true at once, because LifeElements underwriting guidelines are restricted to financial professionals and not publicly accessible ^[45].

The platforms also disagreed on how favorably Lincoln treats mild kidney impairment. One platform identified Lincoln as a target carrier for stable mild-to-moderate proteinuria with normal eGFR above 60, expecting standard to Table 4 outcomes ^[46]. Another described Lincoln as having a risk-stratified approach for stable mild-to-moderate proteinuria with normal eGFR above 60 ^[47]. A third platform found no evidence that Lincoln offers transplant-favorable underwriting compared with carriers with explicit transplant experience ^[48].

Unresolved uncertainties that no platform could close:

• Whether earlier-stage CKD (Stage 3a or 3b) is approved, rated, or declined under LifeElements ^[45].
• Whether MoneyGuard's dialysis or kidney failure exclusion applies to all kidney disease stages or only advanced disease ^[49].
• Whether kidney disease as a secondary condition affects eligibility if the primary condition is otherwise acceptable ^[50].
• Whether Lincoln TermAccel's prescription-history screening flags common CKD medications such as ACE inhibitors, ARBs, phosphate binders, or EPO as automatic full-underwriting triggers ^[48].
• Whether Lincoln offers informal underwriting inquiries for CKD without a formal application record ^[48].
• Lincoln's success rate for kidney disease applicants under LifeElements or universal life products ^[45].

There is also a documented conflict on TermAccel limits. Public materials show different face-amount ceilings across sources and time, including $1 million in one underwriting sheet and $2.5 million in later company and third-party summaries, with issue-age ceilings presented as 18–60 in some materials ^[51]. One independent review notes TermAccel is likely not available in New York and gives older product-limit details that may be outdated ^[54].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What coverage limits and conversion features does Lincoln TermAccel offer a kidney disease applicant who qualifies?
• Does Lincoln Financial Group offer accelerated death benefits or no-lapse guarantees relevant to kidney disease progression?

Lincoln's relevant features for this use case are coverage range, conversion, accelerated death benefits, and no-lapse guarantees. None of them is kidney-specific, and all are conditional on qualifying for the underlying policy.

TermAccel coverage and term choices: 10-, 15-, 20-, and 30-year level-premium periods, a $100,000 minimum face amount, and a $2.5 million maximum face amount, with issue-age limits varying by term and tobacco status ^[55]. TermAccel is not available in New York according to Lincoln's term-life page ^[56].

TermAccel conversion: conversion to qualifying Lincoln permanent life insurance before the end of the level-premium period or before attained age 70, whichever comes first, subject to conversion provisions and products available at that time ^[55].

Accelerated death benefits: Lincoln offers Accelerated Death Benefits riders included on term policies allowing early access if diagnosed with terminal, chronic, or critical illness ^[57]. A Chronic Illness rider allows access to the death benefit if the policyholder cannot perform two activities of daily living ^[58].

No-lapse guarantees: Lincoln offers no-lapse guarantee riders on universal life policies to prevent policy lapse ^[59].

Waiver of premium: available to maintain coverage if the applicant becomes disabled ^[58].

VUL features: AssetEdge VUL provides death-benefit protection, flexible premiums and death benefits, and market-linked investment options ^[60]. Lincoln states that VUL policies involve cost-of-insurance, administrative, premium-load, mortality-and-expense, and asset-management charges; investment value can decline and the policy can require additional premiums to avoid lapse after applicable guarantees expire ^[60].

Underwriting process: applicants with kidney disease will not qualify for accelerated underwriting and must undergo traditional full medical evaluation including a health questionnaire, medical records review, and laboratory testing ^[62]. Lincoln states that lab work may be waived for qualifying applicants and describes automated underwriting, but a kidney-disease applicant should not assume a lab waiver eliminates review of kidney history ^[55].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Lincoln Financial Group cost per month for a kidney disease applicant, and are there policy fees?
• What are the surrender charges and lapse risks on a Lincoln VUL policy for a buyer with kidney disease?

No applicant-specific premium can be verified from Lincoln's public materials for a kidney-disease buyer. Pricing confidence across platforms is low to moderate, and the only published dollar figures are TermAccel policy fees.

TermAccel policy fees are publicly listed: $80 for face amounts from $100,000 to $249,999.99, $90 for $250,000 to $999,999.99, and $70 for $1,000,000 to $2,500,000 ^[64]. TermAccel premiums are level only during the selected 10-, 15-, 20-, or 30-year period; premiums generally increase after that period, and Lincoln describes a face-amount decrease at the end of the level term ^[64].

VUL costs include monthly cost of insurance, administrative expenses, premium-load charges, mortality-and-expense charges, and asset-management fees, with exact amounts depending on the specific contract and prospectus ^[65]. VUL investment returns are not guaranteed; policy value may decline and insufficient value or premiums can lead to lapse after applicable guarantees expire ^[65]. VUL may involve surrender charges during the applicable surrender-charge period, and the exact period and schedule must be reviewed in the contract and prospectus ^[65]. One platform reports surrender charges on universal life policies ranging from 0 to 20 years depending on product, not applicable to term policies ^[66].

Optional riders may carry additional costs. Lincoln specifically lists additional-cost options for children's term coverage and waiver of premium on TermAccel ^[64]. Accelerated death-benefit riders may have a charge when exercised and may have tax or public-benefit consequences ^[64].

Contract and cancellation terms: TermAccel conversion is subject to the stated conversion deadline and availability of qualifying Lincoln permanent policies ^[64]. VUL policy loans, withdrawals, surrender, premium changes, and investment performance can reduce cash value or death-benefit protection and may affect lapse risk ^[65]. Product availability, riders, contract forms, and features vary by state, and Lincoln states that the listed VUL products are not available in New York ^[65]. Standard free-look periods of roughly 10 to 30 days apply depending on state law.

Industry benchmarks, not Lincoln-specific: Stage 1–2 CKD with good control may see standard to mild table ratings (Table 2–4) at competitive carriers; Stage 3a–3b typically falls in a Table 4–8 range; guaranteed-issue coverage for Stage 4–5 or dialysis runs roughly $75–$99 per month for a $25,000 death benefit ^[67]. These are market observations, not Lincoln quotes.

Best Suited For

Questions This Section Answers

• Who is Lincoln Financial Group best suited for among buyers with kidney disease?
• What kidney disease stage and stability profile makes Lincoln Financial Group worth considering?

Lincoln is best suited for applicants with mild or stable kidney impairment who can qualify through conventional full underwriting and who want a large national carrier's term or permanent products.

• Applicants with mild or stable kidney impairment, adequate documentation, and a need for conventional term coverage ^[69].
• Applicants seeking $100,000 to $2.5 million of TermAccel coverage who may qualify for Lincoln's underwriting classes ^[69].
• Applicants with early-stage chronic kidney disease (CKD stages 1–3) with stable kidney function over 12 or more months ^[71].
• Applicants with stable, mild-to-moderate proteinuria and normal eGFR above 60 seeking a risk-stratified underwriting approach ^[72].
• Applicants with permanent insurance, cash-value, or estate-planning objectives who understand VUL investment risk and ongoing policy expenses ^[74].
• Applicants willing to pursue Lincoln LifeElements or universal life products instead of the fast-track TermAccel option ^[71].
• Applicants with resolved acute kidney conditions, such as acute glomerulonephritis with documented full recovery, who may qualify in the standard table 2 range with pricing improvements over time ^[77].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Lincoln Financial Group for life insurance with kidney disease?
• Is Lincoln Financial Group a poor choice for dialysis or end-stage renal disease applicants?

Lincoln is probably not the best fit for applicants whose kidney disease blocks accelerated underwriting, who need guaranteed acceptance, or who want predictable lifetime costs without investment risk.

• Applicants currently on dialysis, with advanced or rapidly worsening kidney disease, or with recent transplant complications ^[78].
• Applicants with stage 4–5 CKD, dialysis, or end-stage renal disease, who are typically uninsurable at Lincoln ^[79].
• Applicants seeking guaranteed acceptance, low-cost final-expense coverage, or a kidney-disease-specific underwriting promise ^[82].
• Applicants who need predictable lifetime costs without investment, lapse, surrender-charge, or policy-loan risk ^[84].
• Applicants seeking simplified-issue or no-exam coverage who want to avoid full medical underwriting ^[85].
• Applicants seeking a hybrid life and long-term care policy, because MoneyGuard lists dialysis or kidney failure as uninsurable ^[87].
• Applicants who need quick approval without medical records review or physician statements ^[86].
• Applicants seeking whole life insurance, which Lincoln does not offer, limiting permanent coverage to universal life variants with investment risk ^[90].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Lincoln Financial Group for a kidney disease buyer who needs guaranteed-issue coverage?
• When should a kidney disease buyer use an independent broker instead of applying directly to Lincoln Financial Group?

Another option may be better whenever the buyer's kidney profile falls outside Lincoln's unpublished comfort zone, or whenever the buyer needs a product type Lincoln does not sell.

• Use an independent multi-carrier broker when the buyer has stage 3 or worse CKD, dialysis, a transplant history, unstable eGFR, proteinuria, or significant diabetes or hypertension ^[91].
• Consider guaranteed-issue or graded-benefit final-expense products when traditional underwriting is declined, while recognizing lower limits, waiting periods, and higher cost per dollar of coverage ^[92].
• Consider another carrier when its underwriting guide or informal inquiry specifically confirms willingness to evaluate the buyer's kidney condition and provides a more favorable projected class ^[91].
• Prefer simpler level-term coverage from a carrier with a clearly favorable preliminary underwriting result when the objective is temporary income or debt protection rather than cash-value accumulation ^[94].
• Consider a carrier with published or widely reported kidney-specific underwriting guidelines if the buyer has moderate to advanced kidney disease ^[95].
• Consider group life insurance through an employer, which often does not require individual medical underwriting ^[95].
• Consider carriers with stronger simplified-issue or graded-benefit offerings if the buyer wants the highest chance of approval despite CKD severity ^[97].
• Consider a carrier with explicit CKD-friendly term underwriting, such as Corebridge Financial, which one platform identified as the best term option for CKD ^[99].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Lincoln Financial Group before signing a kidney disease life insurance contract?

• How can a buyer verify Lincoln Financial Group's underwriting outcome without triggering a formal decline?

• Will Lincoln consider this applicant's exact CKD stage, latest and historical eGFR, creatinine, urine albumin or protein results, cause of kidney disease, treatment, and progression history ^[100]?

• Will Lincoln require an exam, labs, urinalysis, nephrologist records, attending physician statement, imaging, or transplant records ^[102]?

• What underwriting class, exclusions, flat extras, postponement period, or decline outcome is expected before submitting a formal application ^[100]?

• Is Lincoln TermAccel available in the buyer's state, and does the applicant qualify for the accelerated process despite kidney disease ^[105]?

• What exact current contract is being offered: Lincoln TermAccel, Lincoln LifeElements, Lincoln AssetEdge VUL, or another product ^[107]?

• For TermAccel, what are the total premiums during the level period, the post-level-period premiums, the automatic face decrease, and the conversion deadline ^[100]?

• For VUL, what are all policy charges, surrender-charge years, minimum premiums, guaranteed values, lapse provisions, loan provisions, and assumptions used in the illustration ^[107]?

• Are the proposed riders available in the buyer's state, and what do they cost and exclude ^[100]?

• If Lincoln declines or heavily rates the application, can the broker seek informal underwriting opinions from multiple carriers without creating unnecessary application records ^[110]?

• Would guaranteed-issue or graded-benefit coverage be available if traditional underwriting is unsuccessful, and what are its face limit, waiting period, exclusions, and total cost ^[111]?

• Does the applicant's kidney disease co-occur with diabetes, hypertension, or cardiovascular disease, and how will Lincoln review multiple comorbidities ^[113]?

• Is the underlying cause of kidney disease treated differently in underwriting, since some causes may carry higher mortality risk ^[115]?

Final AI Consensus Verdict

Lincoln Financial Group is a mixed fit for life insurance with kidney disease, and the consensus is narrower than the ranking-stage mention count suggests. Two of seven platforms named it during ranking discovery, and it finished seventh overall. Five platforms rated it mixed and two rated it uncertain; none rated it a clear fit.

The strongest reason to consider Lincoln is fully underwritten term and permanent coverage for mild, stable kidney impairment, with TermAccel's $100,000–$2.5 million face range, multiple level-premium periods, and conversion feature ^[116]. The main limitation is that Lincoln publishes no kidney-specific underwriting rules, and its own materials list chronic kidney failure and dialysis as disqualifying for TermAccel, WealthAccelerate IUL, and MoneyGuard ^[117].

Applicants with complex kidney histories should obtain a multi-carrier preliminary underwriting assessment before applying ^[120]. Buyers who want to compare Lincoln against the full field can start with the Life Insurance for Kidney Disease consensus index, which ranks all carriers evaluated for this use case.

For broader context on how health conditions affect coverage, see the life insurance category directory.

How This Review Was Produced

This review was produced from seven AI platform fit evaluations of Lincoln Financial Group for the Life Insurance for Kidney Disease use case, collected on the authoritative run research date of 2026-09-22. Each platform evaluated Lincoln's fit and supplied citations to company-owned and independent sources. The ranking stage counted only platforms that named Lincoln during discovery; the fit stage included all seven platform evaluations regardless of whether Lincoln was named.

Platform-reported research dates are provenance metadata and do not independently prove freshness. One platform reported a research date of 2026-06-01, which differs from the authoritative run date (deepseek). Citations are platform-reported evidence, not independently verified facts. The supplied URLs were collected from platform responses and were not independently validated by the writer stage. No-search model claims require explicit verification before being described as current facts.

Methodology Limitations

• Lincoln does not publish kidney-disease-specific underwriting guidelines, so the central question of whether a kidney-disease buyer would qualify cannot be answered from public sources ^[122].
• No independent source reviewed provided a verified approval, rating, or premium outcome for a Lincoln policy issued to an applicant with chronic kidney disease ^[122].
• Lincoln's LifeElements and universal life underwriting guidelines are restricted to financial professionals and not publicly accessible, creating information asymmetry ^[124].
• Public materials conflict on current TermAccel face-amount and issue-age limits across documents and summaries ^[125].
• Platform-reported research dates differ from the authoritative run date; one platform reported 2026-06-01 (deepseek).
• Independent kidney-underwriting sources describe general market tendencies, not Lincoln-specific decisions; actual outcomes can differ by state, age, laboratory trend, cause of disease, treatment, and other health conditions ^[128].
• The ranking-stage label "Lincoln VUL" does not identify one current contract; Lincoln's current page lists AssetEdge VUL products while also displaying older VUL products not available for new sales ^[130].
• Product availability and underwriting rules can change; the buyer should obtain current written confirmation.